Home » Newsletters » BioWorld

BioWorld

Aug. 31, 1994

View Archived Issues

CORRECTIONS

ALTEON GETS FDA PERMISSION TO BROADEN PHASE III KIDNEY DISEASE TRIAL

OTHER NEWS TO NOTE

APPOINTMENTS AND ADVANCEMENTS

ONCOLOGIX GETS RIGHTS TO DEVELOP MERCK DRUG FOR POTENTIAL CANCER

ICAGEN EXPANDS DISCOVERYAGREEMENT WITH LILLY

SERENDIPITOUS NEW INDICATION DISCOVERED FOR INTERFERON

ROCHE, SYNTEX MERGER CLEARS FINAL FTC HURDLE

VASCULAR THERAPEUTICS SECURES $4M IN FIRST FINANCING ROUND

INDIAN SCIENTISTS HONE VACCINE FOR CONTROL OF HUMAN FERTILITY

GOVERNMENT LABS LEAD IN BIOTECH INVENTIONS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.